INFLECTION BIOSCIENCES LIMITED

Inflection Biosciences is a Dublin-based biotech company dedicated to developing innovative small-molecule therapeutics for cancer, autoimmune and inflammatory diseases. By harnessing dual-mechanism kinase inhibition, the firm aims to deliver more precise and effective treatment options for patients with unmet medical needs.

The company's current pipeline features IBL-202, a novel dual-mechanism kinase inhibitor, and AUM302 (formerly IBL-302), which is being advanced in partnership with AUM Biosciences. Recent milestones include the licensing of PIM-kinase inhibitors to Mysthera Therapeutics and the organisation of a West German Lymphoma Symposium, underscoring Inflection's commitment to scientific collaboration and knowledge sharing.

Through a focus on cutting-edge chemistry and strategic alliances, Inflection Biosciences is positioning itself as a leading player in the development of next-generation therapeutics, aiming to improve outcomes for patients across Ireland and beyond.